Ethical Dilemma: Who Benefits From Calling an Atypical Junctional Melanocytic Proliferation a Melanoma In Situ?

Research output: Contribution to journal › Comment/debate

Original language	English
Article number	e63
Journal	Journal of Drugs in Dermatology
Volume	24
Issue number	11
DOIs	https://doi.org/10.36849/JDD.9286
State	Published - Nov 2025

Access to Document

@article{da96cf32b04e484abb43d016fab25231,

title = "Ethical Dilemma: Who Benefits From Calling an Atypical Junctional Melanocytic Proliferation a Melanoma In Situ?",

author = "Joseph Alcalay and Andrea Gat",

year = "2025",

month = nov,

doi = "10.36849/JDD.9286",

language = "אנגלית",

volume = "24",

journal = "Journal of Drugs in Dermatology",

issn = "1545-9616",

publisher = "Journal of Drugs in Dermatology",

number = "11",

}

TY - JOUR

T1 - Ethical Dilemma

T2 - Who Benefits From Calling an Atypical Junctional Melanocytic Proliferation a Melanoma In Situ?

AU - Alcalay, Joseph

AU - Gat, Andrea

PY - 2025/11

Y1 - 2025/11

UR - https://www.scopus.com/pages/publications/105020894196

U2 - 10.36849/JDD.9286

DO - 10.36849/JDD.9286

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.comment???

C2 - 41187236

AN - SCOPUS:105020894196

SN - 1545-9616

VL - 24

JO - Journal of Drugs in Dermatology

JF - Journal of Drugs in Dermatology

IS - 11

M1 - e63

ER -